UCB at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

UCB takes part in 2 sessions at ACT 2026 in San Antonio. Its program centres on safety pharmacology. It covers updating the ICH S7A international guideline and cross-industry work toward global agreement on secondary pharmacology, which checks a drug's effects on targets it was not meant to hit.

OrganizationACT 2026 Attendance
UCB
Brussels, Belgium
ucb.com
Pharmaceutical companies
Belgian biopharmaceutical company with marketed medicines in neurology, including epilepsy, and immunology.
Poster
Mon Nov 16
5:00pm–6:30pm
Shaping the Future of Safety Pharmacology through ICH S7A Modernization (P212)
Nelson Exhibit Ballroom · Poster P212
Safety pharmacology · Regulatory
Talk
Tue Nov 17
2:45pm–3:15pm
Part of The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10)
Advancing Secondary Pharmacology: Cross-Industry Insights and a Path Toward Global Harmonization (S10-3)
Safety pharmacology

Explore the full ACT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full ACT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from UCB

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction